What Are The Limitations, Unknowns, And Safety Signals
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss
The US Preventive Services Task Force recommends screening beginning at age 45 for average-risk individuals, regardless of GLP-1 use
Heavy metal uptake by plants and cyanobacteria, in Metal Ions in Biological Systems
GLP-1 is released primarily from the ileum and colon in the response to food intake
The bacteriostatic water preservative (0.9% benzyl alcohol) inhibits but does not eliminate bacterial growth, particularly in protein-rich solutions like reconstituted peptides
